Skip to main content

Advertisement

Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation

Fig. 1

Loss of Fn14 coincided with chemoresistance and poor prognosis of HGSOC. (a) and (b) Distribution of Fn14 expression in cisplatin (CDDP) sensitive group and CDDP) resistant group, *p < 0.05. (c) and (d) Survival outcome analysis showed that HGSOC patients with overexpression of Fn14 exhibited better progression-free survival and overall survival compared with those who had low expression of Fn14, **p < 0.01. (e) and (f) Survival analysis showed that patients with overexpression of Fn14 exhibited better progression-free survival and overall survival compared with those who had low expression of Fn14 in CDDP resistant cohort, **p < 0.01, ***p < 0.001, respectively. Fisher’s exact test was performed for clinicopathological data analysies. Values of p < 0.05 were considered as statistically significant. Kaplan–Meier analysis was used performed to evaluate the survival

Back to article page